Document Detail


Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease.
MedLine Citation:
PMID:  17371472     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Some authors proposed to lower the present postglucose GH nadir cut-off (i.e. < 1 microg/l) to that obtained in healthy subjects to establish remission of acromegaly. The aim of the study was to correlate GH nadir with hormonal and metabolic parameters and to confirm the adequacy of the current limit to define disease remission. DESIGN AND PATIENTS: Retrospective study of 40 acromegalic patients cured by surgery, followed by radiotherapy when appropriate, studied at the time of disease remission (Phase 1) and re-evaluated after at least 3 years' follow-up (median 6.5 year, Phase 2). GH nadir was evaluated in 44 sex- and age-matched controls. MEASUREMENTS: Symptom score, pituitary function, neuroradiological imaging, metabolic parameters (BMI, glucose metabolism, insulin sensitivity, lipid profile, blood pressure). RESULTS: The upper limit of the 'normal' GH nadir was fixed at 0.26 microg/l (mean + 2SD of controls). In Phase 1, GH nadir was < 0.26 microg/l in 16 patients (Group A) and > 0.26 microg/l in 24 patients (Group B). Group B had only slightly higher IGF-1 SDS (0.4 +/- 1.0 vs.- 0.1 +/- 1.0, P = ns) and lower body mass index (BMI) than Group A (26.2 +/- 2.4 vs. 30.6 +/- 4.5 kg/m(2), P < 0.005). GH nadir positively correlated with IGF-1 (P < 0.05, r = 0.32) and negatively with BMI (P < 0.05, r = 0.42). In Phase 2, all patients had IGF-1 levels in the normal range and GH nadir < 1 microg/l, both parameters being even lower than those found at the time of remission. No patient had either clinical or neuroradiological evidence of disease recurrence. CONCLUSIONS: The current GH nadir limit is still adequate to define both short- and long-lasting remission of acromegaly, independently of the type of definitive treatment. Patients with the lowest GH nadir should probably be monitored long-term for adequacy of their GH secretion.
Authors:
Cristina L Ronchi; Maura Arosio; Erica Rizzo; Andrea G Lania; Paolo Beck-Peccoz; Anna Spada
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  66     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-20     Completed Date:  2007-09-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  538-42     Citation Subset:  IM    
Affiliation:
Department of Medical Sciences, Institute of Endocrine Sciences, University of Milan, Milan, Italy. cristina.ronchi@unimi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / blood,  surgery*
Adult
Biological Markers / blood
Blood Glucose / analysis
Body Mass Index
Case-Control Studies
Female
Follow-Up Studies
Glucose / diagnostic use*
Glucose Tolerance Test
Growth Hormone / blood*
Hemoglobin A, Glycosylated / analysis
Humans
Insulin / blood
Insulin Resistance
Insulin-Like Growth Factor I / analysis
Lipids / blood
Male
Middle Aged
Reference Values
Remission Induction
Retrospective Studies
Treatment Outcome
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Lipids; 0/Triglycerides; 11061-68-0/Insulin; 50-99-7/Glucose; 67763-96-6/Insulin-Like Growth Factor I; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gender differences in plasma ghrelin and its relations to body composition and bone - an opposite-se...
Next Document:  Follow-up of avidity and titre of anti-myeloperoxidase antibodies in sera from patients with propylt...